Biota Holdings Limited

Biota Holdings Limited (ASX:BTA)(PINK:BTAHY) today reported that it had received revised advice from GlaxoSmithKline (GSK) regarding Relenza sales for the December 2008 quarter. The revised sales were A$27.1 million (US$20.8 million) and indicative royalties were A$1.9 million (US$1.46 million).

Biota Holdings Limited (ASX:BTA)(PINK:BTAHY) today announced that GlaxoSmithKline (GSK) has advised of the current Relenza supply situation in respect to the key market of Japan.

Biota Holdings Limited (ASX:BTA)(PINK:BTAHY) today announced that it had received written notification from GlaxoSmithKline (GSK) that Relenza sales were $20.8 million and indicative royalties were $1.46 million, for the three months ended 31 December 2008.

On Thursday, the Australian shares rose for the third consecutive day led by rallies in overseas markets and strong commodities prices. The benchmark S&P/ASX200 index was up 30.7 points, or 0.88 per cent, at 3,526.2, while the broader All Ordinaries index had gained 26.2 points, or 0.76 per cent, to 3,461.3. The Australian market might lose its recent gains following the heavy fall in Wall St.

Biota Holdings Limited (ASX:BTA)(PINK:BTAHY) today announced that GlaxoSmithKline (GSK) has been awarded a significant contract by the UK Department of Health for 10.6 million treatment courses of RelenzaTM (zanamivir).

Biota Holdings Limited (ASX:BTA)(PNK:BTAHY) announced today the appointment of Mr Richard Hill as a non executive Director.

Biota Holdings Limited (ASX:BTA)(PNK:BTAHY) today announced that the multiple centres involved in the Phase III clinical trail on its long acting neuraminidase inhibitor (LANI) CS-8958 are ready to commence treatment. Patients are expected to enrol into the study progressively throughout the Asian influenza season.

Biota Holdings Limited (ASX:BTA)(PNK:BTAHY) today announced that it had received written notification from GlaxoSmithKline (GSK) that Relenza sales were $27.1 million and indicative royalties were $1.9 million, for the three months ended 30 September 2008.

Biota Holdings Limited (ASX:BTA) and AstraZeneca (LON:AZN) today announced that the 2005 Collaboration and License Agreement with MedImmune has been assigned to AstraZeneca. AstraZeneca has also secured the rights to a number of Asian and Pacific territories not held by MedImmune under the original agreement and for which Biota will receive an additional US$3.5 million payment, plus future royalties.

Biota Holdings Limited (ASX:BTA)(PINK:BTAHY) today announced the commencement of dosing in the first Phase IIa challenge study of BTA798, an orally delivered and potent inhibitor of human rhinovirus (HRV). HRV is the major cause of the common cold and is associated with clinical complications for patients with asthma, cystic fibrosis, chronic obstructive pulmonary disease or a compromised immune function.